

# instantaneous wave free ratio (iFR) and resting index for functional evaluation

A photograph of the Gifu Heart Center building at dusk. The building is a modern, multi-story structure with a grid-like facade of windows, many of which are illuminated from within. A large, flat roof structure extends from the top of the building. To the right, a tall, white cylindrical tower is visible. The sky is a deep blue with some light clouds. In the foreground, there is a paved road and some landscaping.


HITOSHI MATSUO M.D.,

The Department of Cardiovascular Medicine,  
Gifu Heart Center, Gifu, Japan

# Physiological Indices

|          | Resting                                                                                                                                | Hyperemic              |
|----------|----------------------------------------------------------------------------------------------------------------------------------------|------------------------|
| Pressure | Pd/Pa<br>iFR (Pd/Pa wave free period)                                                                                                  | Pd/Pa (FFR)<br>iFR (h) |
| Flow     | Velocity (eg APV)                                                                                                                      | CFVR<br>CFR (thermo)   |
| Combined | Lesion resistance (BSR, HSR)<br>Myocardial Resistance (MVRI, IMR)<br>Wave Intensity Analysis (eg BEW)<br>Pressure/flow loops ( eg PzF) |                        |

# Identification of the naturally occurring diastolic wave-free period using wave intensity




Sen S, Mayet J, Davies JE et al. JACC (in press Nov 2011)


Davies JE, Francis DP, Hughes AD, Mayet J et al. Circulation 2006;113:1767-1778

Davies JE, Parker KH, Hughes AD, Mayet J et al. Circulation 2011;124:1565-1572

# *Using iFR to identify stable resistance phase*



# *Resistance is stable during the wave-free window*






# Necessary condition to measure iFR

- Why should it be measured at rest?
- Why is iFR better than whole cycle Pa/Pd?

# Haemodynamic impact of a coronary stenosis

## Mechanisms of energy dissipation



$$\Delta P = F v + S v^2$$


( $F$  and  $S$  coefficients)

**F**RICTION

**S**EPARATION

$F$  and  $S$  coefficients reflect the anatomical stenosis severity

# A **minimal** velocity is required for stenosis discrimination




Different stenosis severities can generate a similar **low pressure drop (iFR/FFR)** if interrogated with **low velocities**.

Therefore a **minimal** velocity is **required**




# Consistent velocity is required for stenosis discrimination



The **same stenosis** can generate **different pressure drops** (iFR/FFR) depending on the underlying **velocity**.

Therefore the **consistency** of velocity is **essential**

# Hyperemic Versus Baseline Blood Flow



As percent stenosis increases from 10 to 90



Hyperemic blood flow decreases substantially



While base line blood flow does not decrease

Uren N, et al. Relation between myocardial blood flow and the severity of coronary artery stenosis. The New England Journal of Medicine 1994; 330: 1782-1788




Figure 8: iFR should be measured at rest. Hyperemic response such as contrast injection and use of hyperemic agent induce flow increase which result in the iFR value lower. A:iFR at rest B:iFR after contrast injection, C:30seconds after contrast injection, D.iFR at maximum hyperemia induced by ATP infusion.

# CLARIFY an ADVISE sub-study


Why does iFR improve diagnostic accuracy than whole cycle Pd/Pa?

Complete cycle flow





26%  
increase\*

Wave-free flow




Mean velocities from ADVISE




## Complete cycle flow







Increased sensitivity



# ***iFR : A New Adenosine-Independent Index of Stenosis Severity ~ Experience in Gifu Heart Center ~***




# *Patients Characteristics*

|                       |                            |
|-----------------------|----------------------------|
| Patient base analysis | n=191                      |
| age                   | 71.3±9.4                   |
| gender(M:F)           | M 128 F 63                 |
| CCS class             | none 23   90    70     8   |
| HT                    | 128(67%)                   |
| HL                    | 109(57%)                   |
| DM/IDDM               | 66(35%)/9(4.7%)            |
| smoking /past smoking | 50(26%)/37(19.4%)          |
| CKD                   | III a 62 III b 17 IV 2 V 9 |
| HD                    | 9                          |
| OMI                   | 46                         |
| ACS                   | 67                         |
| SVD:MVD               | 1VD 101, 2VD 69, 3VD 19    |
| previous PCI          | 98                         |
| previous CABG         | TCTAP 2015 8               |

# Lesion Characteristics

|                          |             |             |
|--------------------------|-------------|-------------|
| Lesion base analysis     | n=241       |             |
| measured vessel          | RCA 58      | LCA 183     |
| MI related               | 12          |             |
| Lesions with stable pt   | 155 (64.7%) |             |
| Lesions with unstable pt | 85 (35.3%)  |             |
| FFRmyo                   | 0.74 ± 0.14 |             |
| FFR ≤ 0.80               | 157 (65.1%) |             |
| iFR                      | 0.83 ± 0.18 |             |
| MLD                      | 1.20 ± 0.40 |             |
| Ref VD                   | 2.87 ± 0.65 |             |
| LL                       | 24.1 ± 14.1 |             |
| %DS                      | TCTAP 2015  | 57.8 ± 10.5 |

# Correlation of iFR with FFR






# *Diagnostic characteristics of iFR in all*

**All lesions**

**N=241**



**iFR Best cutoff : 0.90**

Sensitivity : 77.1%

Specificity : 79.7%

P.P.V : 87.7%

N.P.V : 65.0%

**Accuracy: 78.0%**


# Consistent iFR cut-points

*IFR value with best classification for  $FFR \leq 0.80$*


|                                      |      |
|--------------------------------------|------|
| ➤ ADVISE-Registry(n=339)             | 0.89 |
| ➤ South Korean Study(n=238)          | 0.90 |
| ➤ RESOLVE(n=1593)                    | 0.90 |
| ➤ ADVISE- <i>in Practice</i> (n=392) | 0.90 |
| ➤ ADVISE 2 (n=689)                   | 0.89 |
| ➤ GHC (n=241)                        | 0.90 |

FDA Labeling iFR = 0.89

# Correlation of iFR with FFR



# Excellent iFR-FFR classification match using independently validated algorithm



- n>3000 stenoses
- Independent core-lab blinded analyses
- Investigators studies
- Multi-centre collaborative studies

## case1 : iFR and FFR Why discrepant?

73 y.o female

PHx : none

PI : asymptomatic. MDCTCA

Problem list

#1. HT #2. Ascending Aortic replacement due to TAA.

#3. CAA aneurysm #4. VA aneurysm #5. CKD. #6.  
effort angina

MDCTCA findings


#1. intermediate focal stenosis in proximal RCA

#2. intermediate stenosis in mid LAD

Cr : 1.4mg/dl eGFR : 36 ml/min/1.43m<sup>2</sup>



## case1 : iFR and FFR Why discrepant?






0:06



**iFR™**  
**1.00**

| List of Runs | iFR  | FFR  |
|--------------|------|------|
| 11:13:44 AM  | 1.00 |      |
| RCA Distal   |      |      |
| 11:14:09 AM  |      | 0.78 |
| 11:18:41 AM  |      | 0.75 |
| 11:19:55 AM  |      | 0.75 |
| 11:40:53 AM  | 0.99 |      |
| 11:41:43 AM  |      | 0.93 |
| 11:45:04 AM  |      | 0.93 |



Live

Options

Save Frame

Settings

Patient

FFR

iFR™

Select Mode  
2015/4/28

TCTAP 2015

FFR PIM

0:25

**FFR** **0.75**


Pd/Pa **0.75**

Pa:iPa **85:128**

Pd:iPd **64: 97**

HR **70**

| List of Runs    | iFR  | FFR  |
|-----------------|------|------|
| 11:13:44 AM     | 1.00 |      |
| RCA Distal      |      |      |
| 11:14:09 AM     |      | 0.78 |
| RCA Distal      |      |      |
| 11:18:41 AM     |      | 0.75 |
| RCA Distal      |      |      |
| 11:19:55 AM     |      | 0.75 |
| RCA Distal      |      |      |
| 11:40:53 AM     | 0.99 |      |
| Post RCA Distal |      |      |
| 11:41:43 AM     |      | 0.93 |
| Post RCA Distal |      |      |
| 11:45:04 AM     |      | 0.93 |
| Post RCA Distal |      |      |






Options


Save Frame

# ***Pressure drop depends on Flow***




The general equation relating pressure loss,  $\Delta P$ , to flow velocity,  $V$ , is:

$$\Delta P = FV + SV^2 \quad (1)$$




$r=0.863$  (95%CI: 0.589 - 0.685),  $p<0.001$




$r=0.537$  (95%CI: 1.183 - 1.787),  $p<0.001$






$r=0.273$  (95%CI: 0.556 - 1.489),  $p<0.001$

# Resting pressure measurements provide a better estimate of hyperaemia flow




# Flow adds significant benefit to FFR in predicting outcomes



FFR significance  $\leq$  0.80  
CFR significance < 2.0

# Vasodilators *do not* improve physiological diagnostic accuracy



1. Van de Hoef et al. Circ Cardiovasc Interv. 2012;5(4):508-14
2. Sen et al. J Am Coll Cardiol. 2013;61(13):1409-20

3. Van de Hoef Euroint. (*in press*)
4. Sen et al. J Am Coll Cardiol. 2013;62(6):566

5. Petraco et al. Circ. Int. (*in press*)
6. de Waard et al. (ACC 2014)

# FFR vs iFR

|                             | FFR                       | iFR                        |
|-----------------------------|---------------------------|----------------------------|
| Concept                     | myocardial flow reserve   | coronary vessel resistance |
| Necessary condition         | steady minimum resistance | constant flow velocity     |
| measurement                 | maximum hyperemia         | resting state              |
| ischemia cutoff             | 0.8                       | 0.89                       |
| correlation with CFR        | poor                      | fair                       |
| linkage with clinical event | DEFER, FAME, FAME II      | FLAIR (ongoing)            |

# FLAIR trial

Functional Lesion Assessment of Intermediate stenosis to guide Revascularisation

|                                   |                                                                                                           |
|-----------------------------------|-----------------------------------------------------------------------------------------------------------|
| <b>Main sponsor:</b>              | <b>Imperial College London</b>                                                                            |
| <b>Funders:</b>                   | <b>Unrestricted Educational grant from<br/>Volcano Corporation</b>                                        |
| <b>Study coordination centre:</b> | <b>Imperial College London</b>                                                                            |
| <b>NRES reference:</b>            | <b>TBC</b>                                                                                                |
| <b>Principal Investigators:</b>   | <b>Justin Davies &amp; Javier Escaned</b>                                                                 |
| <b>Study Chairman:</b>            | <b>Manesh Patel</b>                                                                                       |
| <b>Medical Lead:</b>              | <b>Sayan Sen</b>                                                                                          |
| <b>Steering Committee:</b>        | <b>Eric Van Belle, Farrel Hellig, Raj Kharbanda,<br/>Martin Mates, Hitoshi Matsuo, and<br/>Nob Tanaka</b> |

**Evaluation including cost, complication, procedure time, as well as pt satisfaction**

# Study design

Intermediate lesion requiring physiological assessment  
In ACS : intermediate *non-culprit* lesion

1:1 Randomisation

**FFR**  
guided PCI

**iFR**  
guided PCI

FFR > 0.8  
Defer PCI

FFR ≤ 0.8  
Perform PCI

iFR > 0.9  
Defer PCI

iFR ≤ 0.9  
Perform PCI

30 day, 1, 2 and 5yr follow-up



**Thank you for your attention!!!**

